Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07192939 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary Fibrosis

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Oct 2025 to Oct 29, 2025 · Eligibility criteria revised · Site details revisedv2 Show 3 more changesShow less
    • Start date changed from estimate of Oct 2025 to Oct 29, 2025
    • Eligibility criteria revised
    • Site details revised

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the efficacy and safety of HRS-9813 in subjects with pulmonary fibrosis。
Trial Details
NCT Number NCT07192939
Lead Sponsor Guangdong Hengrui Pharmaceutical Co., Ltd
Conditions IPF and PPF
Enrollment 270 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov